Nowroozi Ali, Momtazmanesh Sara, Rezaei Nima
School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Tehran, Iran.
Front Med (Lausanne). 2023 Mar 24;10:1126491. doi: 10.3389/fmed.2023.1126491. eCollection 2023.
The COVID-19 pandemic is ongoing and places a substantial burden on healthcare systems worldwide. As we further shed light on different disease characteristics, we identify more and more groups of people at higher risk of poor COVID-19 outcomes. Metabolic-associated fatty liver disease (MAFLD) (previously non-alcoholic fatty liver disease or NAFLD) is a common metabolic disorder characterized by fat accumulation and liver fibrosis. Given its close correlation with metabolic syndrome, an established risk factor for severe COVID-19, it is necessary to investigate its interplay with the novel coronavirus. In this study, we review the available data on COVID-19 prognosis, treatment and prevention options in patients with MAFLD, and the effect that the disease and the pandemic have on MAFLD care. Furthermore, we point out the gaps in the current literature to accentuate the work that needs to be done to improve MAFLD care during the pandemic and beyond.
新冠疫情仍在持续，给全球医疗系统带来了沉重负担。随着我们对不同疾病特征的进一步了解，我们识别出越来越多感染新冠病毒后预后较差的高危人群。代谢相关脂肪性肝病（MAFLD）（以前称为非酒精性脂肪性肝病或NAFLD）是一种常见的代谢紊乱疾病，其特征是脂肪堆积和肝纤维化。鉴于其与代谢综合征密切相关，而代谢综合征是新冠重症的既定风险因素，因此有必要研究其与新型冠状病毒之间的相互作用。在本研究中，我们回顾了MAFLD患者新冠预后、治疗和预防方案的现有数据，以及该疾病和疫情对MAFLD护理的影响。此外，我们指出了当前文献中的空白，以强调在疫情期间及之后改善MAFLD护理所需开展的工作。
